DexCom earnings beat by $0.03, revenue topped estimates
Dawn Christine Maroney, the President of Alignment Healthcare, Inc. (NASDAQ:ALHC), recently sold shares of the company amounting to a total value of $420,292. The transactions, which took place on March 12, involved a sale of 26,858 shares at a weighted-average price ranging from $14.72 to $15.715 per share, and an additional 385 shares sold at a weighted-average price ranging from $15.72 to $15.76 per share. The sale comes as ALHC stock has shown remarkable strength, delivering a 214% return over the past year and trading near its 52-week high of $16.25. InvestingPro analysis shows the company’s market capitalization now stands at $2.96 billion. These sales were executed to fulfill tax withholding obligations related to the vesting of restricted stock units, as noted in the filing. Following these transactions, Maroney holds 2,276,732 shares directly. According to InvestingPro, the stock is currently trading slightly above its Fair Value, with 10+ additional ProTips available to subscribers, offering deeper insights into ALHC’s financial health and market position.
In other recent news, Alignment Healthcare Inc. reported its fourth-quarter 2024 earnings, surpassing analysts’ expectations with an EPS of -0.16 compared to the forecast of -0.18. The company’s revenue also exceeded projections, reaching $701.2 million against the expected $674.97 million. This robust performance contributed to a 48% year-over-year increase in total revenue, amounting to $2.7 billion for the full year. Notably, the company achieved its first year of adjusted EBITDA profitability, with membership growing by 59%, driven by expansion outside California. Looking ahead, Alignment Healthcare has provided guidance for 2025, projecting revenue between $3.72 billion and $3.78 billion, marking a 40% year-over-year growth at the midpoint. Additionally, Piper Sandler and Raymond (NSE:RYMD) James have expressed confidence in the company’s future, with Piper Sandler raising its price target to $21 and maintaining an Overweight rating, while Raymond James increased its target to $19 with a Strong Buy rating. These developments reflect Alignment Healthcare’s strategic growth and operational achievements, positioning it for continued expansion in the Medicare Advantage market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.